CD8A and neoplasm: Meanwhile, BAY1082439′s anti-PI3Kδ activity can preferentially inhibit tumor-associated Tregs and B cells, alleviating Treg-mediated immunosuppression and lymphotoxin-mediated CRPC growth30,52 (Fig. 3 and Supplementary Fig. 4B and Supplementary Table 3), and consequently activating cytotoxic CD8+ T cells.